EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Updates and Review of Neoadjuvant Therapy for Resectable Pancreatic Cancer

William Cobb, Daniel Rozefort, Chunghun Ji, Suhani Sehgal, Armando Rosales, Rajesh Sehgal

Oncology · 2025

DOI: 10.1159/000548583 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology, 2025. Verfasst von William Cobb und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, AdventHealth Orlando, Orlando, Florida, USA, william.cobb.md@adventhealth.com. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Pancreatic Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Pancreatic adenocarcinoma (PDAC) is a disease process that carries high morbidity and mortality and is suspected to supplant colorectal cancer as the second leading cause of cancer-related death in the USA. Resectable disease is considered no tumor contact with the celiac axis, common hepatic artery, or superior mesenteric artery and less than 180-degrees contact with portal vein or superior mesenteric vein. The current standard of care for resectable disease is surgery. Summary: There is an ongoing paradigm shift to consider neoadjuvant therapy (NAT) for initially resectable disease and this review aims to summarize the updates in NAT for resectable pancreatic cancer. We performed a literature search of NAT for resectable PDAC and reviewed pertinent literature for current treatment regimens, clinical trials comparing NAT to up-front resection, and other modalities in the treatment of PDAC. Key Messages: Retrospective studies, recent completed prospective studies, and ongoing trials are showing an increased consideration for NAT for resectable PDAC compared with up-front surgery. Additionally, immunotherapy, cell therapy, and matrix-depleting therapy are promising new avenues in the treatment of pancreatic cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyPancreatic NeoplasmsAdenocarcinomaHumansAntineoplastic Combined Chemotherapy ProtocolsPancreatectomy

Stichwörter der Autor:innen

Neoadjuvant therapyPancreatic adenocarcinomaResectable pancreatic cancer

Autor:innen und Institutionen

  • Department of General Surgery, AdventHealth Orlando, Orlando, Florida, USA, william.cobb.md@adventhealth.com.
  • Department of General Surgery, AdventHealth Orlando, Orlando, Florida, USA.
  • Winter Park High School, Winter Park, Florida, USA.
  • Department of Surgical Oncology, AdventHealth Cancer Institute, Orlando, Florida, USA.
  • Director of Medical Oncology at AdventHealth Winter Park, Department of Hematology and Oncology, AdventHealth Orlando, Orlando, Florida, USA.

Zitieren

APA

Cobb, W., Rozefort, D., Ji, C., Sehgal, S., Rosales, A., & Sehgal, R. (2025). Updates and Review of Neoadjuvant Therapy for Resectable Pancreatic Cancer. Oncology. https://doi.org/10.1159/000548583

Vancouver

Cobb W, Rozefort D, Ji C, Sehgal S, Rosales A, Sehgal R. Updates and Review of Neoadjuvant Therapy for Resectable Pancreatic Cancer. Oncology. 2025. doi:10.1159/000548583

BibTeX
@article{Cobb2025,
  author = {Cobb, William and Rozefort, Daniel and Ji, Chunghun and Sehgal, Suhani and Rosales, Armando and Sehgal, Rajesh},
  title = {Updates and Review of Neoadjuvant Therapy for Resectable Pancreatic Cancer},
  journal = {Oncology},
  year = {2025},
  doi = {10.1159/000548583}
}
Kostenlos starten →